AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...

Health equity is an ambitious goal, but the drive to deliver life-changing innovation to all eligible patients is ...

The industry is now entering the next era by embedding AI directly into the software field teams’ use every day. The step ...

Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der ...

Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.

Medicus Pharma has announced the completion of patient enrollment for its phase 2 SKNJCT-003 trial, evaluating the safety and ...

Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...

For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to ...

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to ...

Clicks and engagement only tell part of the story. In this webinar, pharma leaders discuss how to move beyond traditional ...

Building a trusted data foundation The starting line for any successful AI journey is data readiness and quality. Before ...